An educational enduring online activity provided by i3 Health has provided efficiency and knowledge gains encompassing the evolving landscape of therapeutic strategies for graft-versus-host disease (GVHD). Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the sk...

The FDA has approved ibrutinib (Imbruvica®, Pharmacyclics LLC) for treatment of pediatric patients with chronic graft-versus-host disease (cGVHD) following failure of one or more lines of systemic therapy. "Pediatric cGVHD, a potentially debilitating, life-threatening complication of allogeneic hematopoietic stem cell transplantation, has limited treatment options," wrote Marco Zecca, MD, Director of the Pediatric Oncology/Hematology Unit at the Fondazione IRCCS Policlinico San Matteo in Italy, ...